BUND FINANCE

BUND FINANCE › Stocks › DGX

Quest Diagnostics Incorporated (DGX)

NYSE · Stock price, chart and technical analysis

US$259.69+3.34 (+1.30%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:01 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$256.35
OpenUS$254.38
Day rangeUS$253.15 – US$261.46
52-week rangeUS$171.18 – US$263.19
Market capUS$28.57B
Volume1.30M
50-day averageUS$242.22
200-day averageUS$216.44
Beta0.55
Last dividend per shareUS$3.38

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$10.8BUS$9.9BUS$9.3BUS$9.9BUS$11.0B
Net incomeUS$2.0BUS$946.0MUS$854.0MUS$871.0MUS$992.0M
EPS (diluted)15.537.987.527.698.75
Gross margin39.0%34.7%33.2%32.9%31.9%
Operating margin22.1%14.5%13.6%13.6%14.5%
Net margin18.5%9.6%9.2%8.8%9.0%
Free cash flowUS$1.8BUS$1.3BUS$864.0MUS$909.0MUS$1.4B
Total debtUS$4.8BUS$4.7BUS$5.5BUS$7.1BUS$6.9B
CashUS$872.0MUS$315.0MUS$686.0MUS$549.0MUS$420.0M

Compound annual growth: revenue 0.6% · net income -16.0% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E25.9x17.4x27.1x
EV / EBITDA14.8x11.2x16.5x
Operating margin14.6%—3.6%
Net margin9.5%—-0.0%
Debt / equity1.20—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Quest Diagnostics Incorporated

SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
CEOJames E. Davis
Employees57,000
IPO date1996-12-17

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health pl…

www.questdiagnostics.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice